Congress' Year-End Appropriations Package Brings FDA Legislative Changes, Leaves Unresolved Policy Issues - Life Sciences, Biotechnology & Nanotechnology
In a break with past precedent, last year's Food and Drug Administration (FDA) user fee reauthorization legislation did not contain significant FDA policy changes.
Source: mondaq.com
